Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Teva Reports Second Quarter 2021 Financial Results
July 28, 2021 7:00 AM EDTRevenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 million 2021 revenue outlook revised lower to reflect ongoing impact of COVID-19; all other key components reaffirmed: Net revenues of $16.0 - $16.4 billion vs. previous range of $16.4 - $16.8 billion Adjusted EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0 - $2.3 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:... More
